Artelo Biosciences presented positive metabolite profiling data for its lead drug candidate ART26.12 at a medicinal chemistry conference. The data from a recent clinical study showed only three metabolites at low levels, with the main metabolite having similar biological activity to the parent drug and no safety concerns. This low-risk metabolite profile suggests simpler and less costly future development, reinforcing ART26.12's potential as a non-opioid analgesic for chemotherapy-induced peripheral neuropathy. The findings support continued clinical advancement of ART26.12 with confidence in its safety and pharmacokinetics.
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
Alibaba and Baidu shares rose after Apple received approval from China's Cyberspace Administration to include Apple Intelligence, integrating Alibaba's Qwen AI model and Baidu's AI features into Apple devices in China. This partnership allows users t...
